Aggregating human platelets contract isolated rings of canine coronary artery without endothelium, but relax rings with intact endothelium. We performed experiments to identify the substances released from platelets responsible for these effects. The contraction in rings without endothelium was reduced by treating the platelets with the thromboxane synthetase inhibitor, dazoxiben, or treating the vessels with the thromboxane-receptor antagonist, SQ 29548. The serotonergic antagonist, methiothepin, also reduced the platelet-induced contraction. The combination of methiothepin plus dazoxiben or SQ 29548 caused a further inhibition. The endothelium-dependent relaxation to platelets during contractions evoked by prostaglandin F2. was nearly abolished by the ADP-and ATP-scavenger, apyrase. It was not inhibited by methiothepin, which antagonizes endothelium-dependent relaxations to serotonin. Thus, both serotonin and thromboxane A2 contribute to the direct activation of coronary smooth muscle by aggregating human platelets, whereas adenine nucleotides are the principal mediators of the endothelium-dependent relaxation.
Introduction
Isolated canine coronary arteries denuded of endothelium contract to aggregating canine platelets. In contrast, platelets cause an endothelium-dependent relaxation of the same arteries (1) (2) (3) . Both serotonin (e.g., 4) and thromboxane A2 (e.g., 5) can contract coronary vessels and may contribute to the plateletinduced contraction. The relaxation caused by canine platelets is due principally to adenine nucleotides (ADP and ATP) (3), although serotonin released from the platelets might contribute (1, 2) . Human platelets contain more than twice the total quantity of adenine nucleotides and less than half the serotonin compared with canine platelets (6) . The present study was designed to determine whether aggregating human platelets also induce both endothelium-dependent relaxations and endothelium-independent contractions of coronary vascular smooth muscle and, if so, to identify the mediators of both responses.
Methods
Tissue preparation. Left circumflex coronary arteries were removed from mongrel dogs of either sex weighing 15-30 kg, which had been anestheAddress correspondence to Dr. Vanhoutte, Department of Physiology and Biophysics, Mayo Clinic, Rochester, MN 55905.
Receivedfor publication 2S October 1985 and in revisedform 9 April 1986. tized with sodium pentobarbital (30 mg/kg i.v.) and exsanguinated. The vessels were immediately placed in cold modified Krebs-Ringer bicarbonate solution (millimolar composition: NaCl, 1 8.3; KCl, 4.7; CaCl2, 2.5; MgSO4, 1.2; KH2PO4, 1.2; NaHCO3, 25.0; calcium disodium edetate, 0.026; glucose, 11.1; control solution). Rings 4-6 mm long were cut, with up to eight rings from the same animal being studied in parallel as control and treatment groups. Some rings were denuded ofendothelium by inserting a pair of fine forceps into the lumen and gently rolling the ring back and forth on a Krebs-Ringer-wetted paper. This procedure did not alter significantly the maximum tension the vessels could produce when contracted with 40 mM KCl solution (average increase in tension, 7.9±1.2 and 6.0±0.8 g in rings with and without endothelium, respectively; n = 10).
Organ chamber experiments. Rings were suspended in organ chambers made of nonsiliconized glass and filled with 15 ml of control solution maintained at 370C and continuously bubbled with 95% 02/5% CO2. Isometric tension was measured by Gould UC2 strain gauges and recorded on a polygraph. Rings were gradually stretched in small increments up to a basal tension of 10-11 g (shown in previous experiments to be the optimum tension for isometric contraction under these conditions; 2, 3). They were then contracted repeatedly, by increasing the KCI concentration in the bath by 20 mM, until the response was stable.
After repeated rinses with control solution to restore basal tension, all vessels were contracted with prostaglandin F2a (2 X 10-6 M), and tested for the presence of functional endothelium by the addition of acetylcholine (10-6 M) (7, 8) . Rings from which the endothelium had been removed showed no change in tension upon addition of acetylcholine, whereas rings with endothelium relaxed to basal tension; rings not meeting these criteria were excluded.
The rings, after repeated rinses, were equilibrated for a further 30 min in the presence of antagonists. To exclude adrenerglc effects of serotonin (9) , all experiments were conducted in the presence ofpropranolol (10-6 M) and prazosin (5 X 10-' M). Apyrase (0.67 U/ml) was added to the bath immediately before the addition of platelets; the concentration used here has little or no direct effect on the tension of the rings.
Platelet preparation. The blood of nine healthy nonsmoking male volunteers taking no medications was drawn from the antecubital vein into citrate anticoagulant to yield final concentrations of 9.3 mM sodium citrate/0.7 mM citric acid/14 mM dextrose (10) . The blood was centrifuged for 40 min at 100 g at room temperature and the platelet-rich plasma was pipetted off. An equal volume of cold citrate anticoagulant solution (93 mM sodium citrate, 7 mM citric acid, 105 mM dextrose, and 5 mM KCl, pH 6.5) was added to the platelet-rich plasma, and the mixture was centrifuged for 20 min at 500 g. The supernatant was discarded, and the remaining platelet pellet was resuspended in a small volume ofthe second citrate anticoagulant mixture and kept on ice until use. A platelet count ofthis suspension was then obtained (Coulter Electronics, Inc., Hialeah, FL), and the volume ofthe suspension was adjusted so that when added to the organ chamber (in a dilution of 1:40 or higher) the resulting platelet concentration in the bath was 70,000/,Ol. When added to the organ chambers, the platelets aggregated upon exposure to glass, the collagen of the cut vessel surfaces, and the calcium in the Krebs-Ringer solution, while being stirred with bubbling by the gas mix- Serotonin determination. Samples of fluid were withdrawn from the organ baths 5 min after addition of platelets. 0.5 ml of the fluid was added to 120 ,ul of cysteine (1% by weight in distilled water) and proteins precipitated by adding ZnSO4 and NaOH and centrifuging at 3,000 g for 30 min at 40C. The resulting supernatant was frozen until analysis. On the day of analysis, the supernatant was filtered through centrifugal microfilters (Bioanalytical Systems, Inc., West Lafayette, IN) with regenerated cellulose membranes (0.2-Mum pore size). The amine in the resulting supernatant was quantitated by reverse-phase high pressure liquid chromatography with electrochemical detection (12) .
Thromboxane B2 determination. l-ml aliquots of the fluid collected 5 min after addition of platelets were centrifuged (3,000 g, 10 min 4C) and frozen until analysis. They were then brought to pH 3.5 with 1 N hydrochloric acid. Thromboxane B2 was extracted using octadecylsilyl columns (Bond Elut C-18; Analyti-Chem International, Harbor City, CA) by the method of Powell (13) . Further ( 14) .
Results
Basal tension. Unstimulated rings of coronary artery without endothelium contracted on exposure to aggregating platelets, reaching a peak tension which averaged 26.8±9.4% of the tension induced by KCl (40 mM) (Figs. 1, 2) . Peak tension was reached an average of 3.5 min after addition of the platelets, which was followed by a gradual decline in tension.
The 5HT,-and 5HT2-serotonergic antagonist (15) , methiothepin M), present in the bath solution significantly depressed the contraction in rings without endothelium. Treatment of the platelets with the selective thromboxane synthetase inhibitor (16), dazoxiben, also significantly inhibited the plateletinduced contraction. In combination, methiothepin plus dazoxiben caused a significantly greater inhibition of the plateletinduced contraction than either methiothepin or dazoxiben alone. Methiothepin or the combination of methiothepin plus dazoxiben converted the response of endothelium-denuded rings from a contraction into a gradual relaxation (Fig. 1 A) . Likewise, the thromboxane receptor antagonist (17) SQ 29548 (10-6 M) in the organ bath significantly inhibited platelet-induced contractions, and in combination with methiothepin (10-6 M) caused a gradual decline in tension upon addition of platelets which was nearly identical to that produced by dazoxiben and methiothepin (Fig. 1 B) .
Addition of the platelet suspension to the organ bath is accompanied by foam formation. If the active tone of denuded coronary rings was eliminated by relaxation with papaverine (3 X l0-4 M), generation of foam by the addition of dazoxibentreated platelets in the presence of methiothepin caused gradual decreases in measured tension qualitively similar to those seen in rings at basal tension not treated with papaverine (data not shown).
Concentration-response curves to serotonin. Cumulative addition of serotonin to the organ bath (10-9 to 10-4 M) caused contraction ofcoronary rings without endothelium, with a maximal tension -20% of that produced by KC1 (40 mM). This contraction was not significantly affected by the presence of dazoxiben (l0-4 M) in the organ bath but was slightly reduced by SQ 29548 (10-6 M) though this was not significant below 10-' M serotonin (Fig. 3) . The concentration-response curve to serotonin was shifted approximately 230-fold to the right by methiothepin (10-6 M) (Fig. 3) .
Contracted rings. Quiescent rings of coronary artery with endothelium showed an immediate relaxation below basal tension on exposure to aggregating platelets (Fig. 2) . To better study these relaxations, rings were contracted with prostaglandin F2a (2 X 10-6 M).
Rings without endothelium consistently showed a transient further increase in tension after exposure to aggregating platelets; = 42±5% of response to 40 mM KCI; other groups did not differ significantly. All rings were taken from seven dogs; in each case, significance was determined by paired t test between appropriate subgroups of paired rings taken from the same animals. The difference between the responses of control rings with and without endothelium was significant at all points; between control rings with endothelium and rings treated with apyrase, at all points except 0.5 min; between control rings with endothelium and rings treated with methiothepin, at no points; and between rings treated with apyrase and rings treated with apyrase plus methiothepin, at no points.
din F2a (n = 10) nor the relaxation to platelets (n = 6) was affected significantly by the serotonergic antagonist, methiothepin (10-6 M), in the bath solution (Figs. 4, 5) . However, the platelet-induced relaxation was significantly inhibited by apyrase (0.67 U/ml), an ADPase and ATPase. The effect of the combination of apyrase plus methiothepin was not significantly different from that of apyrase alone (Figs. 4, 5) .
The platelet-induced relaxation was significantly augmented by treatment of the platelets with dazoxiben (3.7 X lO-' M) (Fig. 6 ).
Assay ofserotonin. Aggregating platelets released serotonin into the bath fluid, at a concentration of 35.2±2.5 ng/ml (-2 X I0-7 M), measured 5 min after addition ofplatelets. The release ofserotonin was not significantly inhibited by either the presence of methiothepin (10-6 M) in the bath fluid, the incubation of the platelets with dazoxiben (3.7 X l0-3 M), or both (Fig.  7, top) .
Assay ofthromboxane. Thromboxane B2 levels measured in the bath fluid were 2.2±0.5 ng/ml (5.9 X l0-9 M) 5 min after addition ofplatelets. The release ofthromboxane was not affected by the presence of methiothepin (10-6 M) in the bath, but was significantly reduced by incubation of the platelets with dazoxiben (3.7 X l0-3 M) (Fig. 7, bottom) .
Discussion
This study shows that human platelets trigger contraction of canine coronary arterial rings from which the endothelium has been removed. Two substances are released by aggregating platelets that are known contractile agents in certain vascular smooth muscle preparations: serotonin and thromboxane A2. In particular, serotonin can contract isolated canine coronary arteries (e.g., 2, 4, 18, 19) . Thromboxane A2 released from plate- were not significantly different in any of the four groups. "Methiothepin" indicates the presence of methiothepin (106 M) in the organ bath at the time of platelet addition; "dazoxiben" indicates incubation of the platelets with dazoxiben (3.7 X 10-3 M) before addition to the bath. Bottom, production of thromboxane B2 by aggregating human platelets, as determined by radioimmunoassay of the same samples withdrawn from the organ bath 5 min after addition of platelets (70,000/4d); n = 6. Concentrations of thromboxane were not significantly affected by methiothepin (106 M) in the bath but were significantly and markedly suppressed by treatment of the platelets with dazoxiben (3.7 X 10-3 M).
ent study shows that both serotonin and thromboxane A2 are released during aggregation of human platelets under the experimental conditions imposed, and that both contribute to the contractions they evoke in coronary rings; Moulds et al. (21) reached similar conclusions with human digital arteries. The concentration of serotonin measured in the bath in our experiments is above the EC50 determined for the contraction to the monoamine. Further evidence that serotonin contributes to the contraction to human platelets is provided by the observation that the serotonergic antagonist, methiothepin (at a concentration that prevented the contractile response of coronary rings to a concentration of serotonin equivalent to that found in the bath, but did not inhibit the release of thromboxane from the platelets), inhibited the contractile response to platelets. Evidence pointing to a contribution by thromboxane A2 to the platelet-induced contraction is that treatment ofthe platelets with the selective thromboxane synthetase inhibitor, dazoxiben (at a concentration that markedly reduced the generation of thromboxane B2), also decreased the contractile response of endothelium-denuded rings to aggregating platelets. This could not be attributed to a nonspecific effect on the release of serotonin or on the responsiveness ofthe vessels to the monoamine, since neither of these was affected by dazoxiben. Dazoxiben did not inhibit platelet aggregation in this system, to judge from the fact that dazoxiben-treated aggregating platelets induced a greater (rather than lesser) endothelium-dependent relaxation than control platelets; this observation suggests that the direct constrictor effect of thromboxane A2 weakly opposes the endothelially mediated relaxation.
Confirmation of the role of thromboxane A2 in the plateletinduced contraction is provided by SQ 29548. This compound selectively antagonizes thromboxane receptors, but does not inhibit ADP-induced aggregation of human platelets or the formation of thromboxane A2 by human platelet membrane preparations (17) . At a concentration which did not significantly depress contractile responses to serotonin, SQ 29548 inhibited the platelet-induced contraction of endothelium-denuded coronary rings. The degree of inhibition was similar to that caused by dazoxiben-treatment of the platelets. Likewise, the degree of inhibition caused by the combination of SQ 29548 and methiothepin was almost identical to that caused by dazoxiben plus methiothepin.
The modest, gradual loss of tension of rings without endothelium in the presence of combined thromboxane and serotonergic inhibition could reflect the release of an as-yet unidentified vasodilator substance by the platelets. However, it may as well reflect an artifact of the experimental system. Traction exerted by rising foam on the thread connecting the vessels to the force transducer would unload the transducer, as suggested by similar platelet-suspension-induced declines of measured tension in rings treated with papaverine to eliminate active tone.
This study shows that human, like canine platelets (1) (2) (3) 22) , can induce an endothelium-dependent relaxation of isolated coronary arteries. Earlier studies (1, 2, 22) suggested that serotonin, which can induce endothelium-dependent relaxations in the canine coronary artery ( 19) , is released from canine platelets and might contribute to the endothelially mediated relaxation. Since human platelets contain less than half the secretable serotonin that canine platelets do (6), it seems unlikely that the monoamine would be a major contributor to the endotheliumdependent relaxation to human platelets. In confirmation ofthis, methiothepin, a serotonergic antagonist that at the concentration used abolishes the endothelium-dependent relaxation ofcoronary arterial rings to serontonin (3, 23) , failed to affect the relaxation induced by human platelets.
Another substance released from aggregating platelets that can induce endothelium-dependent relaxations is platelet-activating factor; however, such relaxations occur at concentrations of the substance that are unlikely to occur in vivo (24) . More probable candidates as the mediators of this relaxation are the adenine nucleotides, ATP and ADP. These nucleotides can induce potent, endothelium-dependent relaxations in canine femoral and coronary arteries (3, 8) . They appear to be the principal mediators of the relaxation of coronary arteries induced by canine platelets (3). Human platelets contain more than twice the total content of adenine nucleotides (ATP plus ADP) that canine platelets do (6) . Apyrase is an enzyme that hydrolyses ATP and ADP to AMP and adenosine (the latter two products being much less potent relaxing agents of large coronary arteries) and consequently inhibits the endothelium-dependent relaxation of rings ofcoronary artery to exogenous ADP without affecting responses to serotonin (3) . Apyrase present in the organ chamber at the time of platelet aggregation nearly abolished the human plateletinduced relaxation. The modest, transient relaxation persisting in the presence ofapyrase is most readily explained by ADP and ATP temporarily escaping degradation by the enzyme, as this residual relaxation is not prevented by methiothepin. These findings strongly suggest that adenine nucleotides are the principal mediators of the endothelium-dependent relaxation of coronary arterial rings induced by human platelets.
The nature of the signal for relaxation transferred from the endothelium to the smooth muscle in response to stimulation by ADP or ATP (or to stimulation by a variety of other pharmacological agents) remains unknown. Bioassay experiments have suggested that it is a diffusable factor (25) . It is apparently not prostacyclin or another cyclo-oxygenase or lipoxygenase product since, at least in the canine femoral artery, ATP-induced relaxations are not inhibited by indomethacin, 5-8-1 1-14-eicosatetraenoic acid (ETYA), or quinacrine (26) . Likewise, in the coronary artery, relaxations to adenine nucleotides released by aggregating canine platelets are not inhibited by meclofenamate (3) .
Thus, a variety of vasoactive substances released from aggregating human platelets can be identified: thromboxane A2 and serotonin, which favor contraction, and the adenine nucleotides (ATP and ADP) which favor relaxation in the presence of endothelial cells. In the coronary artery, the balance of their effects depends on the presence or absence of endothelium. In its presence, the net effect is relaxation, whereas if it is removed or damaged, contraction ensues. We therefore speculate that coronary vasospasm may be, in at least some instances, due to endothelial dysfunction. In one animal model, intact endothelium reduced vasoconstriction to serotonin in blood-perfused canine coronary arteries (27) ; in another, intact endothelium prevented the development of platelet-induced coronary spasm in fluorocarbon-perfused isolated rabbit hearts (28) . Our results suggest that blockade ofthe synthesis by platelets ofthromboxane A2, or of the appropriate vascular serotonergic or thromboxane receptors, may be of therapeutic benefit in coronary vasospastic disease; both may be required for full effect.
